Peppermint oil beat placebo in the meta-analysis. The biggest single trial did not.

Peppermint oil is the home remedy for irritable bowel syndrome that actually has trials behind it. Whether those trials say it works depends heavily on which one you read — and the two most important pieces of evidence point in opposite directions.

The case for: a meta-analysis that looked convincing

The most comprehensive pooling to date gathered 12 randomised trials with 835 patients [s1]. On the question of global symptom improvement, the analysis of seven trials found peppermint oil roughly doubled the chance of getting better: a risk ratio of 2.39 versus placebo, with a 95% confidence interval of 1.93 to 2.97 [s1]. For abdominal pain specifically, six trials gave a risk ratio of 1.78 (95% CI 1.43 to 2.20) [s1]. Both results were highly statistically significant, and — unusually for a meta-analysis — showed no measurable heterogeneity between trials [s1].

The authors translated this into a number needed to treat of three for global symptoms and four for abdominal pain [s1]. That is a strong-looking number: treat three people and one who would otherwise have stayed symptomatic gets relief. Side effects were mild and no more common than with placebo in a statistical sense — 9.3% of peppermint-oil patients versus 6.1% on placebo, a risk ratio of 1.40 whose confidence interval (0.87 to 2.26) crossed one [s1]. The paper concluded peppermint oil was "safe and effective" for IBS [s1].

The case against: the trial built to modern standards

Then came the largest, most rigorous single trial. Researchers at four Dutch hospitals randomised 190 patients diagnosed by the current Rome IV criteria to small-intestinal-release peppermint oil, ileocolonic-release peppermint oil, or placebo for eight weeks [s2]. Crucially, they used the endpoint regulators now demand: the US Food and Drug Administration's definition of abdominal pain response — at least a 30% fall in the weekly average of worst daily pain, in at least four of the eight weeks [s2].

On that endpoint, peppermint oil did not beat placebo. The small-intestinal-release group had a 46.8% response rate, the ileocolonic group 41.3%, and placebo 34.4% — with P values of .170 and .385, both comfortably non-significant [s2]. The co-primary endpoint, overall symptom relief as defined by the European Medicines Agency, showed no difference either [s2]. A trial designed specifically to test peppermint oil to a high standard came back null on the outcome that mattered most.

Why the two disagree

The gap is a lesson in how IBS evidence ages. The trials feeding the meta-analysis were mostly smaller and older, used varied and often looser outcome measures, and carried a higher risk of bias [s1]. The Dutch trial used a large sample, a modern diagnosis, and the strict, regulator-approved endpoint — and a placebo response of 34.4%, which is exactly the kind of large placebo effect that swamps modest real benefits in gut-brain disorders [s2].

Neither result is fake. The honest reading is that peppermint oil's effect, if it exists, is smaller than the older literature suggested — real enough to show up when you pool loosely defined outcomes, too small to clear a strict threshold in one well-run trial.

What this means if you want to try it

Peppermint oil remains one of the lower-risk things to test for IBS. It is cheap, available without prescription, and the pooled safety data found no significant excess of side effects over placebo [s1]. Enteric-coated or delayed-release capsules exist because plain peppermint oil relaxes the valve at the top of the stomach and can worsen heartburn; the formulations studied are designed to release lower down [s2].

A reasonable approach is a time-limited trial — a few weeks of an enteric-coated product — treating it as something that helps a meaningful minority rather than a reliable fix. If it works for you, the placebo response in the trials is a reminder that part of the benefit may not be the oil; that does not make the relief less real. If it does nothing after a month, the strongest single trial suggests you are not an outlier [s2].

The bottom line

Peppermint oil is the rare IBS folk remedy with genuine randomised evidence on both sides of the ledger. A large meta-analysis says it beats placebo with a number needed to treat of three [s1]; the best-designed single trial says it does not clear the modern bar [s2]. That is not a reason to dismiss it, but it is a reason to keep expectations modest and the trial period short.

Sources

• The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data — BMC Complementary and Alternative Medicine, 2019-01-17
• Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome — Gastroenterology, 2019-08-27